Astrazeneca Pharma India Ltd
NSE:ASTRAZEN
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
Astrazeneca Pharma India Ltd
NSE:ASTRAZEN
|
222.5B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
969.6B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
588.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
293.6B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
250.1B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
239.2B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
301.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.9B USD |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Astrazeneca Pharma India Ltd
Glance View
AstraZeneca Pharma India Ltd., a pivotal name in the Indian pharmaceutical landscape, is an integral arm of the global biopharmaceutical titan, AstraZeneca PLC headquartered in Cambridge, UK. The company has woven itself into the fabric of healthcare by consistently delivering novel medicines designed to combat a range of illnesses that include oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory ailments. In India, AstraZeneca Pharma has carved out a reputation for not only introducing cutting-edge research and development capabilities but also adapting its global innovations to fit the unique demands of the local market. By leveraging a robust pipeline of therapeutic solutions, the company plays a crucial role in the intersection of healthcare and technology, aiming to improve patient outcomes through personalized medicine and bioscience-led innovations. The business model of AstraZeneca Pharma India is anchored in its commitment to research-driven innovation and strategic partnerships. Revenue streams are tightly interlinked with the company’s ability to successfully commercialize its extensive portfolio of patented medicines. AstraZeneca focuses on maintaining strong relationships with healthcare professionals and stakeholders, which are pivotal in driving prescriptions and ensuring the adoption of its novel therapies. Sales and distribution channels are fortified through collaborations with hospitals, pharmacies, and other healthcare providers, ensuring a broad reach across the country. The company continues to invest in its capabilities to educate and train medical professionals, thus enhancing its influence in the medical community and reinforcing its position as a market leader in providing life-saving medications.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Astrazeneca Pharma India Ltd is 42.8%, which is below its 3-year median of 50.1%.
Over the last 3 years, Astrazeneca Pharma India Ltd’s Gross Margin has decreased from 63.3% to 42.8%. During this period, it reached a low of 41.4% on Mar 31, 2025 and a high of 63.7% on Jun 30, 2023.